

2025 Global NF Conference Abstract Submission - RESOURCE DOCUMENT

June 21 - 24, 2025 | Washington, D.C.

Abstract submission for the 2025 NF Conference is now open!

Abstracts will be reviewed by a scientific committee and those with the highest scores will be invited to present their work orally as Platform Presentations and remaining accepted abstracts will be invited for Poster Presentations.

Acceptance of an abstract requires an in-person presentation. Authors who are unable to travel to Washington, D.C. may designate a co-author or fellow member of their scientific team to present on their behalf.

General Information:

- Abstracts must be submitted through the vFairs platform.
- Submitting authors may select whether their abstracts should be considered for:
 - a platform (oral) presentation ONLY;
 - o a poster presentation ONLY; or
 - either a platform OR a poster presentation.
- When using abbreviations within the body of the abstract, spell out the word in full at first mention and follow with the abbreviation in parentheses.
- You will receive a confirmation email once your abstract is submitted.
- No changes can be made after the abstract submission deadline.
- Presenters will only be invited once the abstract submission is accepted.
- Invited presenters will be required to present in-person, and all presentations will be accessible on the virtual platform.
- For assistance with abstract submission, please contact nfconference@ctf.org.

As you prepare your submission, please note the following:

Accepted abstracts will be published physically and digitally, constituting public disclosure. For more information on public disclosure as it relates to future publications & patent filings from your research, please consult with your institution's Technology Transfer/Patenting & Licensing Office.

Acceptance does not include costs of conference registration, travel, or the printing of materials. Please complete your attendee registration for the NF Conference <u>HERE.</u>

All NF-relevant abstracts are welcome; however, those aligned with the themes for the 2025 conference will receive a prioritized review. Themes include:

- Microenvironments & the Immune Response,
- Next-Generation Treatments,
- Management of Diverse Clinical Manifestations of NF, and
- Translational Models & Novel Research Approaches

New Abstract Categories

Based on feedback we've received from NF Conference attendees, we are changing our abstract submission process to include a more robust categorization of submissions. This will allow us to provide more structure to our assignment of reviewers, placement of posters in the hall, and organization of the abstract book.

In addition to the standard NF type and basic/preclinical vs clinical categories, we have included further categories below.

NF TYPE

- Neurofibromatosis type 1
- NF2-related schwannomatosis
- Non-NF2 schwannomatosis
- Disease agnostic

RESEARCH CATEGORIES

- 1. Basic / Preclinical Research
 - 1.1. TUMOR BIOLOGY AND DISEASE MECHANISM
 - 1.1.1. Tumor microenvironment
 - 1.1.2. Immunology / Immune response
 - 1.1.3. Cell signaling and signaling/metabolic pathways
 - 1.1.4. Cellular interactions and communication
 - 1.1.5. Gene regulation and epigenetics
 - 1.1.6. Tumor cell of origin / cell lineage
 - 1.1.7. Biomarkers
 - 1.1.8. Disease progression and metastasis
 - 1.1.9. Other
 - 1.2. STRUCTURAL BIOLOGY
 - 1.2.1. Protein structure
 - 1.2.2. Other
 - 1.3. DRUG DISCOVERY AND DEVELOPMENT
 - 1.3.1. Target identification and validation
 - 1.3.2. Lead discovery and development

- 1.3.3. Cell models
- 1.3.4. Patient-derived xenografts
- 1.3.5. Genetically engineered mouse models
- 1.3.6. Animal models
- 1.3.7. Organoids and 3D culture models
- 1.3.8. Novel alternative methods (NAMs)
- 1.3.9. Other

1.4. THERAPEUTICS

- 1.4.1. Drug repurposing
- 1.4.2. Precision medicine / Targeted therapy
- 1.4.3. Gene therapy
- 1.4.4. Immunotherapy
- 1.4.5. Nutraceuticals
- 1.4.6. Other

1.5. BIOINFORMATICS AND COMPUTATIONAL OMICS

- 1.5.1. All omics studies (genomics, proteomics, transcriptomics, metabolomics)
- 1.5.2. Data libraries
- 1.5.3. Computational biology, predictive technology, and Al-based approaches
- 1.5.4. Other

1.6. SHARING PLATFORMS

- 1.6.1. Data sharing platforms and initiatives
- 1.6.2. Biobanks
- 1.6.3. Other

2. Clinical Research

- 2.1. Bone abnormalities
- 2.2. Cognition / Behavioral / Learning
- 2.3. Cutaneous and subcutaneous neurofibroma
- 2.4. Plexiform neurofibroma
- 2.5. Malignant peripheral nerve sheath tumors (MPNST)
- 2.6. Glioma (optic pathway, non-optic)
- 2.7. Schwannoma
- 2.8. Ependymoma
- 2.9. Meningioma
- 2.10. Pain
- 2.11. Other
 - 2.11.1. Quality of Care/Quality Improvement
 - 2.11.2. Symptoms, Toxicities, Patient-reported outcomes, treatment management
 - 2.11.3. Therapeutics, clinical trials in progress, clinical trials completed, case reports
 - 2.11.4. Diagnostics / imaging
 - 2.11.5. Real-world evidence / Natural history
 - 2.11.6. Other

Abstract Submission Guidelines for the 2025 NF Conference

Please read carefully, as there are several changes from prior abstract calls.

Submission Timeline:

- March 1, 2025: Abstract Submission Deadline
- March 2-31, 2025: Abstract Review Period
- April 1, 2025: Acceptance/Rejection Notices Sent
- June 7, 2025: Presenter Material Submission Deadline
- June 7-15, 2025: Material Review Process
- June 21-24, 2025: See you in DC!

Submission Guidelines

- Please upload your abstract as a Word document. The naming convention should be as follows, using the presenting author's information (if different from submitting author): Last name First name First keyword of title.
- Abstracts should not exceed 400 words or 1-page with figures (including purpose, methods, results, and conclusion).
- Figures, if used, should be high resolution (at least 300 dpi) and embedded in the abstract PDF file.
- No more than 4 figures are permitted per abstract.
- Legends should be included for each figure (not included in the 400 word limit).
- Define all abbreviations used.
- Avoid using proprietary names for drugs.
- NOTE: Carefully consider which topics and subtopics you select to categorize your submission. CTF reserves the right to recategorize an abstract.

Abstract Structure

- 1. Authors: Full name, academic credentials, and institutional affiliation for all authors.
- 2. Funding: Indicate the granting agency and mechanism whose fiscal support made the research possible.
- 3. Disclosures: Any relevant financial relationships for author(s). If chosen for CME accreditation, additional disclosure documentation may be required.
- 4. Title: Objectively describe the study as a single sentence.
- 5. Purpose: Statement of why the study was conducted.
- 6. Methods: Brief description of how the research was conducted.
- 7. Results: Summary of key findings, to include text and/or images/tables/graphs.
- 8. Conclusion: Interpretation of results and the implications/significance of the study.

Submission Options - "Select Abstract Type"

- PODIUM: Consider for Platform Presentation only
- POSTER: Consider for Poster Presentation only
- ALL: Consider for either Platform or Poster Presentation

Platform (PODIUM or Oral) Presentation

Session Co-Chairs will select abstracts that fit into one of the 2025 Conference themes for Platform Presentations. Each Platform Presenter will have approximately 10 minutes to present their work, with 5 minutes for Q&A, for a total of 15 minutes.

Poster Presentation

Poster presentations will take place during the Poster Session on Sunday, June 22. This format allows attendees to engage directly with poster presenters, providing critical learning and discussion opportunities. The Poster Session will be 2 hours long; refreshments will be served.

In addition to physical posters, digital posters will be uploaded to the NF Conference website beginning in early-mid June as an additional engagement opportunity to allow for virtual Q&A and informal discussions with interested attendees during designated poster sessions.

Authors' Consent and Waiver of Claims

Completion of all required information in the online abstract submission system serves as an agreement. It certifies the NF Conference abstract submitter's understanding of the rules for participation contained in the online abstract submission program and affirms that:

- 1. They assign all copyrights of the abstract in all forms and media to CTF, effective if and when it is accepted for publication by CTF.
- 2. They confirm that the abstract contains no material the publication of which violates any copyright or other personal or property right of any person or entity, and acknowledge that CTF is relying on this representation in publishing this abstract.
- 3. They have obtained consent of all other authors to transfer copyright on their behalf, and indemnify CTF for any breach of this representation.
- 4. In the case of a "work made for hire" (a work prepared by an employee within the scope of his or her employment or commissioned as a work for hire under a written agreement), an authorized representative of the copyright owner must agree to the copyright transfer to CTF. The submitting author must obtain consent of the copyright owner and indemnify CTF for any breach of this representation.

--OR-

• U.S. Federal Employment: If all named authors are officers or employees of the U.S. and the abstract was written as part of his or her official duties, it is not subject to U.S. copyright. Authors must also agree to items 2, 3, and 4 above. If such an abstract is not published by CTF, this form will not take effect.

Abstract Review Criteria

Reviewers will evaluate abstract according to the following criteria (B & C to be more heavily weighted):

- A. Quality of Presentation: To what extent does the author demonstrate clarity and thoroughness in the abstract, including sections for Background, Methodology, Results, Conclusions?
- B. Innovation: To what extent does the abstract submission investigate a new area, use novel methodology or outcomes, or present a new perspective on existing knowledge?
- C. Impact: To what extent is the topic important and of interest to attendees of the NF Conference and the findings are a substantive contribution to the field of NF?